COVID-19 and diabetes in children

Article information

Ann Pediatr Endocrinol Metab. 2022;27(3):157-168
Publication date (electronic) : 2022 September 30
doi :
Department of Pediatrics, University of Chieti, Chieti, Italy
Address for correspondence: Francesco Chiarelli Department of Pediatrics, University of Chieti, Via dei Vestini, 5, I-66100 Chieti, Italy Email:
Received 2022 June 29; Revised 2022 August 16; Accepted 2022 August 22.


This review describes the impact of coronavirus disease 2019 (COVID-19) in children and adolescents, investigating changes in diabetes presentation during the COVID-19 pandemic, possible links between severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection and diabetes, and mechanisms of pancreatic β-cell destruction. Although glycemic control in individuals with already known diabetes mellitus did not worsen during the pandemic, there was a worrying increase in diabetic ketoacidosis in children with new-onset diabetes, probably due to containment measures and delayed access to emergency departments. Moreover, new evidence suggests that SARS-CoV-2 has the capacity to directly and indirectly induce pancreatic β-cell destruction, and the risk of newly diagnosed diabetes after COVID-19 increased in both children and adults. While long-term studies continue to follow children with SARS-CoV-2 infection, this review discusses available findings on the relationship between COVID-19 and diabetes. It is important to emphasize the need to maintain close links between families of children with chronic conditions and their pediatricians, as well as to promote early access to healthcare services, in order to reduce dangerous delays in diabetes diagnosis and prevent diabetic ketoacidosis.


· A link between COVID-19 and new diabetes onset was found. Moreover, there was an increase in diabetic ketoacidosis in children with new-onset diabetes. It is important to elaborate new strategies to avoid delays in diabetes diagnosis and to prevent diabetic ketoacidosis.


In December 2019, a new infectious disease was observed in Wuhan, Hubei Province, China, where many cases of unknown-origin pneumonia were reported. The disease, subsequently identified as coronavirus disease 2019 (COVID-19), spread rapidly in China and then across the world. Mainly presenting as a respiratory illness, in older patients or people suffering from underlying conditions COVID-19 is more likely to result in acute respiratory distress syndrome (ARDS), multiorgan failure (MOF), and even death [1]. Long-term sequelae, commonly known as "long COVID," may also be evident in the postacute phase, beyond 4 weeks from the start of symptoms [2].

This new pandemic also affects children. While general symptoms are nonspecific and similar to those caused by other common viral respiratory infections, extrapulmonary manifestations in children have been described in the literature [3].

A link to endocrine disorders was also found. Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) demonstrated the capacity to affect multiple systems other than the respiratory system and data about the endocrine manifestations of COVID-19 eventually emerged. As an example, adrenal dysfunction has been reported and SARS-CoV-2 receptors have been identified in adrenal glands [4]. Abnormalities in thyroid function, associated with low thyroidstimulating hormone and low T3 levels, have been observed in patients with severe disease [5]. Moreover, patients already affected by endocrine disorders were found to face increased risk for severe manifestations of COVID-19.

Studies of COVID-19 cases revealed that obesity, diabetes and uncontrolled hyperglycemia increase the risks of hospitalization, intensive care unit admission, and adverse outcomes of SARS-CoV-2 infection [6-9]. COVID-19 is also associated with worsening diabetes symptoms. During the pandemic, a great number of children received delayed diabetes diagnosis. This new disease altered the presentation of diabetes itself and the severity of diabetic ketoacidosis (DKA) in both patients with known diabetes and those with new-onset disease [10].

A Centers for Disease Control (CDC) study found that children who recover from COVID-19–even children who were positive but asymptomatic–are at higher risk of developing type 1 diabetes (T1D) or type 2 diabetes (T2D) after infection [11]. This increased risk for diabetes in children who had COVID-19 underlines the need to develop adequate preventive measures as well as effective chronic disease prevention programs. It is important to emphasize the need for long-term monitoring of consequences following SARS-CoV-2 infection, including symptoms of new diabetes onset [11].

COVID-19 in children

While initial data showed that children accounted nearly for 1%–5% of diagnosed COVID-19 cases, at the time of writing, reports from the American Academy of Pediatrics suggest that children represent approximately 19% of all cases [12]. Clinical manifestations of COVID-19 cases are typically milder in children compared to ones adults, and their prognosis is better. The disease, when not asymptomatic, often presents with fever, cough, or other moderate upper respiratory tract infection symptoms. Additional manifestations can be diarrhea, vomiting, or other gastrointestinal symptoms. These findings seem to be associated with both limited exposure to the virus among children (due mainly to local lockdowns during the first wave of COVID-19) and host factors [13,14].

Considering that the virus will not stop circulating and will overlap with other contagious diseases, particularly in children, a future challenge will be to differentiate symptomatic COVID-19 in children from influenza or infections caused by other viruses and bacteria [15].

Young children, primarily infants, can be particularly vulnerable to SARS-CoV-2 infection [13] and suffer from severe and critical forms of disease. A small proportion of children develop hyperinflammation, known as Multisystem Inflammatory Syndrome in Children (MIS-C). Patients with MIS-C have a high frequency of gastrointestinal symptoms (71%), including abdominal pain and diarrhea, and have fever as a distinctive tract [16]. Cardiovascular dysfunction is the most frequently described physiological abnormality, leading to hypotension and echocardiographic irregularities. Severity of illness is generally high, often requiring admission to an intensive care unit [16].

Just as in adults, a variable percentage of children experience a broad range of symptoms 3 to 12 weeks after the documented infection. So-called "long COVID" includes symptoms as varied as chest pain, palpitations, headache, brain fog, low mood, and other mental health conditions such as depression and anxiety; in some people there may be more subjective, aspecific symptoms resembling those typical of chronic fatigue syndrome [17]. The prevalence of long COVID varies considerably across studies, due in part to the lack of a distinct definition of "long COVID" itself.

The increase in primary care consultations after COVID-19 infection in all age groups has been highlighted (including up to 6 months after infection in children aged 1–5 years). However, half of children without positive tests also experienced headache, fatigue, sleep disturbance, and lack of concentration during the pandemic [18]. It is a great challenge to distinguish symptoms of long COVID from symptoms attributable to the pandemic itself and to lockdown measures, and the fact that almost all long COVID studies lack a control group is a relevant limitation [17,19].

The only way to limit viral dissemination, specifically during the first waves of COVID-19 (when vaccines were not available), was quarantine. Almost half of the world was under a strict "lockdown"; in Europe, lockdowns began reducing viral circulation after the first 3 weeks and continued to show results as the days went by [20]. School closure led to the loss, for a considerable number of children, of access to school-based healthcare, special services, and nutrition programs. School closures also resulted in increased stress, anxiety, sadness, and depressive symptoms among children. Moreover, in the first phase of the lockdown all physical activities (both indoor and outdoor) were shut down and together with the prevalence of a more sedentary lifestyle, caused increases in children's body mass index (BMI) and augmented prevalence of obesity [21].

The CDC analyzed data from IQVIA's Ambulatory Electronic Medical Records database and found that persons aged 2–19 years with moderate or severe obesity before the pandemic faced higher rates of increase in BMI [22]. Weight gain, particularly among already overweight and obese children, produces ongoing metabolic variations that increase the risk for T2D, hypertension, and depression. The necessity of obesity prevention and management strategies both during and following COVID-19 pandemic therefore becomes clear [22,23].

It is important not only to promote efforts to fight COVID-19 through immunization and pharmacological treatments, but also to assess preventive strategies and medical care for potentially high-risk populations [24]. Close contact with healthcare professionals should be guaranteed to all children and their parents, with the help of telemedicine if necessary.

COVID-19 and DKA in children

Diabetes mellitus is one of the leading causes of morbidity and mortality in the world, reducing the life expectancy of those affected by its microvascular and macrovascular complications. The Global Burden of Disease (GBD) study found that the prevalence among subjects aged 1-19 years increased from 5.7 million in 1990 to 8.8 million in 2017. Considering all age groups, cases of diabetes have almost doubled since 1990. The GBD study also found that the increasing global burden varied by type of diabetes and region: increases in T1D have mainly affected high income regions such as Europe and the United States [25].

Due to the current COVID-19 pandemic lifestyles have changed drastically worldwide, with physical and psychological consequences. Patients with pre-existing chronic conditions such as T1D have suffered the most in this situation. The presence of a chronic condition is an important risk factor for higher rate of progression to ARDS in hospitalized patients with COVID-19 [7].

There are conflicting data regarding the incidence and the severity of presentation of diabetes during the COVID-19 pandemic. While some reports have noted a decrease in the incidence of T1D, others detected increases in the number of DKA cases and, particularly, severe DKA during the COVID-19 pandemic. DKA is an important metabolic alteration that causes hyperglycemic emergencies in patients with diabetes mellitus. Once thought to be a condition only occurring in patients with T1D, DKA can also occur in T2D, particularly when patients undergo stressful conditions such as surgery, trauma, and infections [26].

The International Society for Pediatric and Adolescent diabetes criteria classify DKA [27] as a condition that comprises:

- Blood glucose > 11 mmol/L (~200 mg/dL);

- Venous pH <7.3 or bicarbonate <15 mmol/L;

- Ketonemia and ketonuria.

DKA severity is defined as follows [27] :

- Mild DKA: venous pH <7.3 or bicarbonate <15 mmol/L;

- Moderate DKA: venous pH <7.2, bicarbonate <10 mmol/L;

- Severe DKA: venous pH <7.1, bicarbonate <5 mmol/L.

Investigations of the prevalence of diabetes and DKA during the pandemic yielded interesting but partially conflicting data. Some studies showed that children and adolescents already diagnosed with T1D did not experience deterioration of glycemic control during the current pandemic and the lockdown period. In children, glucose control actually improved during the pandemic with augmented time in range (TIR) and reductions of average blood glucose level. This improvement reflected the shift to full-time parental control of meals, glycemic levels, and insulin administration [28].

Some retrospective evaluations of glycemic control included individuals with a median age of 14.2 years and T1D in the period that occurred just prior the SARS-CoV-2 outbreak in Italy and during the first lockdown. In these adolescents, glycemic control did not worsen; it actually improved in those who regularly continued physical activity during quarantine. The improvement was attributed to the continuous presence of parents at home and to the reduction of the unpredictability of school and after-school activities [29]. The pandemic, therefore, has not led to a significant worsening in disease control in children who already had diagnoses of diabetes.

Regarding new diabetes diagnoses, in particular T1D, another issue has to be addressed. During the pandemic, there have been significant reductions in pediatric emergency visits. In the United States (US), before 2020, pediatric admissions overall displayed winter predominance, associated with an increase in infectious respiratory conditions. However, during 2020, there was a dramatic decrease in pediatric admissions to emergency departments. A maximum reduction of 45.5% in pediatric admission rates for non–COVID-19–related diagnoses was detected in 2020 with significant reductions in all examined diagnoses except for birth [30]. One explanation of this finding could be fear of contracting COVID-19 and reductions in seasonal infectious diseases due to lockdown and self-isolation [31,32]. The pandemic situation directly and indirectly forced patients with illnesses other than COVID-19 to stay at home. Similar findings have been described in other countries.

T1D is one of the most common chronic diseases in children and its signs and symptoms usually develop quickly. Physicians and parents are pivotal in the prevention of DKA. The key question in this context was about the frequency of DKA during the pandemic. During the COVID-19 pandemic, higher incidences of severe and moderate DKA at T1D initial presentation have indeed been reported (Table 1).

Summary of reviewed studies about the impact of COVID-19 pandemic on diabetes presentation at diagnosis

Initial studies examined the early phase of the pandemic, during which local lockdowns were imposed. In Italy, a cross-sectional study compared data from 53 of 68 centers (77.9%) belonging to the Italian Society for Pediatric Endocrinology and Diabetes (SIEDP/ISPED). Two periods were studied, the first between 20 February and 14 April 2019, and the second between 20 February and 14 April 2020. While there were fewer diabetes cases during the pandemic, the number of DKA and, particularly, of severe DKA cases increased significantly [10].

In a prospective multicenter study, data during the first wave from March to December 2020 from all pediatric diabetes centers in Lombardy, Italy, were examined. The observation period was extended to the next few months during which the restrictions of the first wave were partially eased. They found higher proportions of both DKA and severe DKA (over total DKA diagnoses) during the first wave, probably due to delayed access to Emergency Departments and higher numbers of DKA diagnoses over total T1D diagnoses even during the second wave of the pandemic [33].

These results, showing an increase in the prevalence and severity of DKA in new-onset diabetes, are consistent with reports from other countries. Significant increases in DKA and severe DKA at diabetes diagnosis were reported during the COVID-19 pandemic among children and adolescents in Germany. These findings were attributed to underlying causes such as fear of accessing the health care system and reduced medical services during the lockdown [34]. A Polish study compared 2 groups, from 2019 and 2020. Overall, they observed increased DKA incidence (52% vs. 49% of newly diagnosed T1D), with a further increase in severe DKA in 2020 versus 2019. This increased prevalence of severe DKA was attributed to a combination of factors: lockdown and difficulty contacting health care professionals for non-COVID-19-related diseases, parental unawareness of classic diabetes symptoms, and shorter duration of symptoms in children with DKA [35].

In the United Kingdom, data were collected from several diabetes units (76 from England, 10 from Wales, and 2 from Northern Ireland). The number of children with DKA at diagnosis was higher than in previous reports. It was also estimated that 20% of newly diagnosed T1D cases were detected after a relevant delay related to fear of contracting COVID-19 or to inability to reach healthcare services [32].

An increase in glycosylated hemoglobin among new-onset T1D during the pandemic was reported, along with an 11% increase in DKA diagnoses, in a study of Saudi children. Data from the first year of the pandemic were compared to data from the same period of the previous year [36]. Other studies examined data (for both children and adults) from 7 large US medical centers, finding that DKA frequency increased among T1D patients during the pandemic. During the first (March–May 2020) and second (August–October 2020) COVID-19 waves, higher proportions of patients had DKA compared to the same periods in the previous year (first wave: 7.1% vs. 5.4%, P<0.001; second wave: 6.6% vs. 5.7%, P=0.001) [37]. In another study of 615 children admitted with new-onset diabetes in a tertiary care children’s hospital between March 2018 and December 2020, children admitted to the hospital with new-onset diabetes in the pandemic and post-pandemic period were more likely to present with DKA compared to those in the pre-pandemic period [38].

Interestingly, American studies highlight a significant association between ethnicity and DKA proportion, with more DKA diagnoses in nonwhite children (Black, American Indian and Alaskan Native patients) [37,38]. Increase in DKA severity in T2D was also described during the pandemic among nonwhite children (Black or African America, Hispanic, Latino). These adolescents had worse glycemic and metabolic control overall even before the pandemic, mostly as a consequence of socioeconomic status factors and higher BMI [39].

Such concerning increases in DKA and, specifically severe DKA, must be considered major impacts of COVID-19 pandemic on healthcare systems. In most countries medical resources were shifted towards pandemic management, and telephone contact became the only way to seek medical consultation for other conditions. Patients were recommended to stay at home [40], where parents were often unaware of potentially alarming diabetes symptoms [10] such as the onset of polyuria, nycturia, weight loss, fatigue, and polydipsia. However, these are not the only possible explanations: a distinction must be drawn between children who tested positive for SARSCoV-2 infection and children who did not or for whom tests were not performed.

It is now recognized that diabetes affects the prognosis of COVID-19. Studies have found that a pre-existing diabetes diagnosis did not increase the risk of contracting COVID-19, but diabetes can worsen the outcomes of disease [41]. Poor glycemic control is associated with worse COVID-19 prognosis while improved glycemic control is linked with better outcomes [42]. Another question arises from new reports that seem to demonstrate a link between newly diagnosed diabetes in patients with prior COVID-19 infection. In adults, an increased risk of diabetes was reported as a postacute, long-term consequence of SARS-CoV-2 infection [43]. It remains to be seen whether this condition will persist or be reversible with time.

In children, COVID-19 might lead to diabetes through direct and indirect effects of infection on endocrine and exocrine pancreatic cells and through the hyperinflammation that it promotes, and may lead to ketosis and ketoacidosis [44,45]. In a recent study of newly diagnosed diabetes in children who tested positive for SARS-CoV-2, data from 2 major US medical health insurance claims databases indicated that new diabetes diagnoses were more likely to occur in patients who had COVID-19 in the previous 30 days than those who did not [11]. These results were also traced back to the effects that SARS-CoV-2 infection may have on organs involved in diabetes risk. Moreover, infection helps quicken the transition from prediabetes to diabetes. A limitation of that study was that some patients with highly likely SARS-CoV-2 infections did not have documented positive tests, and might have been misclassified as not having COVID-19 [11]. On the other hand, some studies were conducted without including homogeneous information about SARS-CoV-2 testing status or about the presence or absence of serum antibodies [33,38,46]. This is clearly a source of bias that may lead to inaccurate classification of some patients and result in underestimations of disease effects.

COVID-19 and pathogenetic mechanisms of β-cell destruction

RNA and DNA viruses are known to be potential causal agents for diabetes in people prone to diabetes due to genetic and/or physiologic factors. Multiple pathogenetic mechanisms of β-cell damage have been proposed in animal and human models of diabetes. Some viruses have a tropism for β cells and the infection has the capacity to induce direct cellular lysis. In other cases, the infection promotes inflammation, dedifferentiation [47] of β cells, or turns the infected cell into a target for the immune system [48,49].

The onset of T1D and, in some cases, of fulminant T1D, has been reported during and after acute infection with mumps virus [50], rotavirus [51], enteroviruses, particularly coxsackie virus [52], and many others. Regarding rotavirus infection, with the diffusion of live attenuated rotavirus vaccination a new question arose: could the vaccination itself be associated with T1D? While a triggering connection between some wild-type rotavirus infections and diabetes has been confirmed [51], recent studies found that children exposed to the vaccine did not have a higher risk of developing T1D compared to children who did not receive vaccination against rotavirus [53]. In addition, some studies showed a reduction of prevalence of T1D after the vaccination. In a cohort study of 1,474,535 infants in the US from 2001–2017, there was a 33% reduction in the risk of type 1 diabetes with completion of the rotavirus vaccine series compared to unvaccinated children [54]. Diabetes is not only an independent risk factor for admissions into intensive care unit and related to worse outcomes in patients with COVID-19 [7-9], but SARS-CoV-2 infection is also thought to be a potential causal factor for diabetes.

Coronaviruses are a large group of viruses that belong to Family Coronaviridae, Order Nidovirales. They have been further categorized into 4 strains: α, β, γ, and δ coronaviruses. Like all viruses in Nidovirales, SARS-CoV-2, which belongs to the β-coronaviruses and infects mammals, is an enveloped virus with a single strand, nonsegmented positive-sense RNA genome [55]. It contains 4 structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N). Although not entirely the same, SARS-CoV-2 shares about 82% of its entire sequence with SARS-CoV and MERS-CoV and more than >90% sequence identity for essential enzymes and structural proteins [56].

The entry of viral particles into host cells is mediated by the S glycoprotein that binds to the receptor on host cells [57]. The S protein is structured to form homotrimers that bulge from the viral membrane, giving it the typical crown-like appearance [58].

In SARS-CoV-2 S the trimeric S protein binds to the cellular receptor angiotensin-converting enzyme 2 (ACE2), mediating the fusion of the 2 membranes, viral and cellular [59]. The virus is then primed by proteases; specifically, S protein is cleaved by a host cell furin-like protease into 2 separate subunits, S1 and S2 [55,60]. While furin processes the S1-S2 site, TMPRSS2, a host type II transmembrane serine protease, intervenes in cleavage at the S2 site. Both proteases are fundamental and cannot compensate for each other [61]. Another entry pathway proposed for SARS-CoV-2, the so-called "late" pathway (whereas the "early" one is mediated by furin-like proteases and TMPRSS2), is based on cathepsin, a lysosomal protease that mediates cleavage at the S2 site in the late endolysosome. Cathepsin L, in particular, plays a role in SARS-CoV and SARS-CoV-2 entry [58].

Knowing where ACE2 is expressed supports understanding about SARS-CoV-2 tropism and the mechanisms of susceptibility for SARS-CoV-2 infection. The ACE2 receptor is a carboxypeptidase consisting of 805 amino acids and shares homology with ACE. There are multiple studies of different ACE2 expression levels in airways. It was detected mostly in ciliated airway epithelial cells, suggesting that the infection tends to involve mainly the proximal airways.[62,63].

The protein expression of ACE2 has been observed in various human cell types, tissues and organs (enterocytes, renal tubules, gallbladder, cardiomyocytes, male reproductive cells, placental trophoblasts, ductal cells, eye, and vasculature) [64]. Previous studies suggest that ACE2 is also expressed in pancreatic tissue. Some authors, through the use of multiple reagents and antibodies, showed that ACE2 is expressed in human pancreatic islets and is preferentially expressed in insulin-producing β cells [65]. However, there are other immunohistochemistry studies in which minimal to no expression of ACE2 was detected [66,67], thus decreasing the chance of a direct SARS-CoV-2 infection of β cells through ACE2. Some authors found high expression of ACE2 in pancreatic pericytes and in acinar and islet microvasculature, with no evidence of ACE2 expression by α or β cells. On the other hand, several studies, all conducted using immunohistochemistry, support the expression of ACE2 in pancreatic islets [65,68,69]. The discrepancy may be explained by differences in antibody sensitivity, immunodetection method sensitivity, and tissue preparation methods [65].

As for studies in which ACE2 presence in pancreatic β cells was detected, the expression of the receptor was only observed using 2 out of 3 antibodies tested, with ACE2 islet signal detected using MAB933 and Ab15348 antibodies, while Ab108252 antibody did not show positivity within the islet parenchyma. The explanation provided was that the prevalent ACE2 isoform expressed in the islet was the short one. ACE2, as it has been recently documented, has a 459 amino acid short isoform that can be coexpressed together with the full-length form, which is of 805 amino acids. However, the functional role of this short-length isoform has not been established, although it can potentially interact with the full-length form or with membrane proteins, thus modulating SARS-CoV-2 susceptibility [65].

Other evidence supporting direct pancreatic infection mediated by SARS-CoV-2 is provided by several studies. ACE2 mRNA and protein were found in both endocrine and ductal pancreatic cells. Moreover, upon examining entire pancreatic sections stained with hematoxylin-eosin multiple thrombotic areas were found in SARS-CoV-2 infected subjects, alongside higher levels of pancreatic lipase. In these subjects higher levels (if compared with non-infected controls) of intercellular adhesion molecule 1, ICAM1, a marker of endothelial inflammation and dysfunction, were also found [70].

With regard to mechanisms of pancreatic β-cell damage, viruses may have the potential to activate β-cell intracellular signaling, inducing altered expression of self-antigens on the surface of the cell, thus inducing a process that ends in apoptosis and insulitis [71] (Fig. 1). β-cell destruction may also result after the induction of direct cellular lysis due to a massive pro-inflammatory cytokine response [72]. After the outbreak of the COVID-19 pandemic, the focus has inevitably shifted to potential mechanisms of pancreatic damage directly caused by SARS-CoV-2 infection. Even though there are conflicting data about islet and β-cell expression of markers essential for viral entry, it has been suggested that COVID-19 leads to β-cell destruction also through an indirect effect, damaging the surrounding pancreatic tissue. In some studies conducted using human autopsy tissue, it was found that pancreatic islets of SARS-CoV-2-infected subjects expressed elevated levels of pseudokinase mixed lineage kinase domain-like protein (pMLKL), a hallmark of necroptosis [68].

Fig. 1.

RS-CoV-2 enters the pancreatic β cell and activates β-cell intracellular signaling, inducing processes that end in apoptosis, insulitis, and transdifferentiation into α cells and acinar cells. SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2; ACE2, angiotensin converting enzyme 2; NRP-1, neuropilin-1; PAK, p21-activated kinase; JNK, c-Jun N-terminal kinases; PKR, protein kinase R; ELF2α, eukaryotic translation initiation factor 2 subunit 1; ISR, integrated stress response.

Other authors determined that SARS-CoV-2 infection is associated with morphological and functional changes, including reduced insulin-secretory granules, resulting in reduced insulin content and glucose-stimulated insulin secretion. This dysfunction, alongside with cellular death, causes new-onset diabetes or worsening of pre-existing diabetes [44,73].

Upon infecting primary human islets ex vivo with SARS-CoV-2, some authors observed that the infection resulted in higher chemokine and cytokine expression (CCL2, CXCL1, CXCL2, CCL3, CCL4, CXCL5, CCL8, IL1RN, IL1B). In addition, a β-cell transdifferentiation path was identified: the infection caused a reduction of insulin content and secretion along with a reduction in protein processing and expression [74]. Creating this hyperinflammatory state, COVID-19 may easily induce ketosis and ketoacidosis [57,75]. Case reports and studies, lastly, described the development of necrotic and non-necrotic pancreatitis, and elevations in lipase and amylase during and following the infection [67,76].

To sum up, while not all cases result in the onset of new diabetes, cellular destruction mechanisms that develop during SARS-CoV-2 viral infection contribute to impaired glucosestimulated insulin secretion and global metabolic dysregulation in patients with COVID-19, often worsening the course of the infection.

COVID-19, obesity, and T2D

The prevalence of overweight and obesity is rising worldwide. According to the World Health Organization, in Europe, America, and the Eastern Mediterranean approximately half of the population is overweight or obese. Lower prevalences of obesity are reported in Africa and Asia but with a rising trend [77]. The association between elevated BMI and adverse health consequences is known not only in adults, but also in children and adolescents. Strict connections between abdominal obesity and the incidence of prediabetes, T2D, hypertension, dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and metabolic syndrome have been documented [78-80].

During the COVID-19 pandemic, a study of 432,302 children (ages 2–19 years) found that the rate of BMI increases nearly doubled compared to the pre-pandemic period [22]. This result, consistent with those of other studies, highlights the importance of obesity prevention and management strategies during and after the pandemic period.

In 2020, China was the first country to implement a strict national lockdown to combat the emergence of SARS-CoV-2. This measure was quickly embraced by Italy and, afterwards, by a large number of countries worldwide. At a time when the world was facing a new and unfamiliar disease, vaccines and specific pharmacological treatments were not available and health resources had to be targeted and rationalized, lockdown prove to be an effective measure for virus containment [20,81]. But not without a cost: the unexpected disease outbreak threatened the mental health of both affected and non-affected people [82]. The lockdown had a strong impact on adults, and the burden of this situation on children and adolescents should not be underestimated. Physical and psychological changes were reported in both children and adults especially during the first lockdown, with stricter measures. The main effect was a drastic change in feelings and emotional state. The major reported condition in children was mood instability, often associated with anxiety and with a sensation of fear of getting/of relatives getting COVID-19. Lifestyle changes occurred, with sleep disorders becoming predominant. Increases in screen time were observed, as well as reductions of both indoor and outdoor physical activities [83]. Hence, despite being an effective method as for virus containment, lockdown showed a series of significant negative effects.

In parallel with psychological issues, the COVID-19 pandemic also exacerbated the issue of childhood overweight and obesity. Lockdown restricted all kinds of daily activities with negative changes in eating and sleep behaviors and reductions in physical activity in children and adolescents. These changes have direct effects on body weight, with children who reported decrease in physical activity and increase gaining more body weight [84,85]. The effects were greater in already overweight and obese children who experienced major increases in BMI with a greater risk of metabolic and biochemical changes [85-87].

Questionnaires and telephonic interviews were administered during and after lockdown to gather information about lifestyle, diet, sleep behavior, physical activities, and mental health during the weeks of mandatory home confinement. In a crosssectional study carried out by the pediatric endocrinology department of a tertiary university hospital in Rome, pediatric patients with already elevated BMI had worse diets and greater increase in BMI during lockdown, perhaps due to reductions in the consumption of fresh food, especially fruit and vegetables, associated with higher intake of carbohydrates and junk food during a period in which sleep and activity behaviors also changed dramatically [88]. Comparable results were showed in a longitudinal study, also conducted in Italy, in which adverse variations in eating and activity behaviors were more noticeable in obese children and adolescents [85].

In response to factors both related to the infection and the lockdown, many studies also reported an increase in T2D incidence. In a retrospective study, the frequency of T2D cases grew sharply after the onset of the COVID-19 pandemic. Children with new-onset T2D had a median age at admission of 11.3 years. In particular, the relative frequency of T2D increased significantly in the cohort of children with DKA, and the percentage of moderate DKA was higher among children with T2D than in T1D [38]. Comparable results about T2D and DKA were observed at Children's Hospital, Los Angeles, where the prevalence of DKA increased significantly from <10% to 20% from 2018-2019 to 2020 [89]. Other retrospective studies reported an increased incidence of T2D compared to pre-pandemic years mostly as an indirect effect of the pandemic [90,91]. Interestingly, cases increased among non-Hispanic Black males, mostly due to social and economic disparities that predated the pandemic [91,92]. Lockdown also resulted in quick worsening in glycemic control in patients with already known T2D, unlike children with T1D, who experienced improvement in glycemic values during home confinement [93].

Attention should be focused on the increased incidence of T2D in children and adolescents after lockdown. Most likely, the significant changes in children’s habits during lockdown enhanced the risk of obesity, and the increase of BMI was found to be higher among already overweight and obese children. [84-86] The growth in obesity rate led, at the same time, to an increase in the incidence of T2D [90,91,94].

In the broader perspective, families should be supported and adequate measures should be implemented to help children and young people maintain adequate activity levels together with healthy sleep routines and eating habits, even in a pandemic situation. Strategies to increase awareness about childhood obesity, diabetes, and their management should be implemented, in order to help parents get in touch with healthcare professionals so that children can be diagnosed early [90,95,96]. At the same time, in patients with diagnosed T2D, physicians should be aware of likely changes in dietary habits and in physical activities triggered by the pandemic context. The impact of these changes on glycemic control and on glycemic TIR should be considered and the dosages of antidiabetic drugs should be adjusted, if necessary, to maintain control of the disease without enhancing the risk of complications.


The COVID-19 pandemic has raised several challenges for healthcare professionals globally, as well as for patients. Studies in adults that have shown how patients with diabetes are more predisposed to a severe course of COVID-19 [97]. Other data suggest that SARS-CoV-2 infection may result in metabolic dysregulation even in subjects without a history of diabetes, and the infection may not only worsen pre-existing diabetes, but also cause new diabetes onset [98].

For children, current data are considerably more limited. Although clinical manifestations of COVID-19 in children are typically milder in comparison to adults, endocrine imbalances may appear in children too. During the pandemic, although T1D diagnoses did not increase, more children with new-onset T1D presented with DKA and severe DKA at diagnosis. The increase in DKA at diagnosis most likely resulted from delays in diagnosis due to difficultly accessing healthcare during the pandemic and lack of parental recognition of common symptoms of diabetes [99].

Reductions in emergency department access have been reported in most countries, mainly during the first, strictest lockdown [30-32]. The fear of contracting COVID-19 and advice given by healthcare workers not to visit emergency departments have been suggested to explain the advanced clinical presentation of diabetes in children and adults [100]. However, the pandemic did not lead to worsening of disease control in children with already diagnosed T1D, who probably benefitted from the fact that, with their parents at home, their blood glucose levels were monitored more strictly. Moreover, fluctuations attributable to less proper nutrition and to the unpredictability of outdoor activities (school, physical activity) fell short [29]. In addition to the increase of DKA at T1D diagnosis, COVID-19 indirectly raised T2D risk in children and adolescents through increases in body weight and BMI that can be traced back to the effects of the pandemic and mandatory home confinement [38,88,90].

In patients with documented SARS-CoV-2 infection, associations between COVID-19 and diabetes were found not only for adults, but also for children. COVID-19 might lead to diabetes through direct attack of pancreatic β cells and, indirectly, through cytokine storm [11,98]. To combat this inauspicious trend, a number of precautions may be taken. Pediatricians and healthcare workers in general should point out to parents that, even in a pandemic context, the risks of avoiding emergency departments and hospital should be considered alongside the risk of contracting COVID-19. This concept should be stressed using the right communication strategies in order to contain the dangers caused by delayed or missed emergency healthcare recourse during a pandemic [101].

In order to highlight potential symptoms that should warn parents that their children need care, new campaigns for diabetes and DKA prevention could be effective. An example is the massive campaign for DKA prevention fostered in Parma in the period between 1991 and 1997, which retained effectiveness even 8 years after its initial promotion [102]. Periodically renovating these informational campaigns can be a useful strategy to warn parents, emphasizing the necessity to seek medical help and thus shortening the latency period between the first symptoms and the diagnosis.

In the current pandemic, children with chronic conditions such as diabetes need uninterrupted access to medical care, through telemedicine if necessary, and should be monitored strictly both by parents and pediatricians so that they maintain healthy nutrition, continue regular physical activity, and continue their glucose monitoring even when confined at home. The ISPED has proposed some practical recommendations for pediatric patients with diabetes during COVID-19 pandemic [103].

Appropriate treatment adjustments should be made in individuals already having diabetes and in newly diagnosed patients. While long-term follow-up studies will further elucidate the association between COVID-19 and diabetes, in clinical practice it is vital to extend the follow-up period of these children. Clinicians should consider new-onset diabetes as a possible consequence of the metabolic imbalance caused by SARS-CoV-2 infection.


Conflicts of interest

No potential conflict of interest relevant to this article was reported.


This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author contribution

Conceptualization: SP; FC; Data curation: SP; FC; Project administration: SP; FC; Visualization: SP; FC; Writing - original draft: SP; Writing - review & editing: SP; FC


1. Tezer H, Bedir Demirdağ T. Novel coronavirus disease (COVID-19) in children. Turk J Med Sci 2020;50(SI-1):592–603.
2. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med 2021;27:601–15.
3. AlSamman M, Caggiula A, Ganguli S, Misak M, Pourmand A. Non-respiratory presentations of COVID-19, a clinical review. Am J Emerg Med 2020;38:2444–54.
4. Mao Y, Xu B, Guan W, Xu D, Li F, Ren R, et al. The adrenal cortex, an underestimated site of SARS-CoV-2 infection. Front Endocrinol (Lausanne) 2021;11:593179.
5. Kumar B, Gopalakrishnan M, Garg MK, Purohit P, Banerjee M, Sharma P, et al. Endocrine dysfunction among patients with COVID-19: a single-center experience from a tertiary hospital in India. Indian J Endocrinol Metab 2021;25:14–9.
6. Puig-Domingo M, Marazuela M, Giustina A. COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology. Endocrine 2020;68:2–5.
7. Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol 2020;8:782–92.
8. Rezaei N, Montazeri F, Malekpour MR, Ghanbari A, Azadnajafabad S, Mohammadi E, et al. COVID-19 in patients with diabetes: factors associated with worse outcomes. J Diabetes Metab Disord 2021;20:1605–14.
9. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020;55:2000547.
10. Rabbone I, Schiaffini R, Cherubini V, Maffeis C, Scaramuzza A, ; Diabetes Study Group of the Italian Society for Pediatric Endocrinology and Diabetes. Has COVID-19 delayed the diagnosis and worsened the presentation of type 1 diabetes in children? Diabetes Care 2020;43:2870–2.
11. Barrett CE, Koyama AK, Alvarez P, Chow W, Lundeen EA, Perrine CG, et al. Risk for newly diagnosed diabetes >30 days after SARS-CoV-2 infection among persons aged <18 years - United States, March 1, 2020-June 28, 2021. MMWR Morb Mortal Wkly Rep 2022;71:59–65.
12. American Academy of Pediatrics. Children and COVID-19: state level data report [Internet]. Itasca (IL): c2022 [cited 2022 Apr 19]. Available from:
13. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 among children in China. Pediatrics 2020;145e20200702.
14. Mansourian M, Ghandi Y, Habibi D, Mehrabi S. COVID-19 infection in children: a systematic review and meta-analysis of clinical features and laboratory findings. Arch Pediatr 2021;28:242–8.
15. Assaker R, Colas AE, Julien-Marsollier F, Bruneau B, Marsac L, Greff B, et al. Presenting symptoms of COVID-19 in children: a meta-analysis of published studies. Br J Anaesth 2020;125:e330–2.
16. Radia T, Williams N, Agrawal P, Harman K, Weale J, Cook J, et al. Multi-system inflammatory syndrome in children & adolescents (MIS-C): a systematic review of clinical features and presentation. Paediatr Respir Rev 2021;38:51–7.
17. Radtke T, Ulyte A, Puhan MA, Kriemler S. Long-term symptoms after SARS-CoV-2 infection in children and adolescents. JAMA 2021;326:869–71.
18. Magnusson K, Skyrud KD, Suren P, Greve-Isdahl M, Størdal K, Kristoffersen DT, et al. Healthcare use in 700 000 children and adolescents for six months after covid-19: before and after register based cohort study. BMJ 2022;376e066809.
19. Zimmermann P, Pittet LF, Curtis N. How Common is long COVID in children and adolescents? Pediatr Infect Dis J 2021;40:e482–7.
20. Alfano V, Ercolano S. The efficacy of lockdown against COVID-19: a cross-country panel analysis. Appl Health Econ Health Policy 2020;18:509–7.
21. Chaabane S, Doraiswamy S, Chaabna K, Mamtani R, Cheema S. The impact of COVID-19 school closure on child and adolescent health: a rapid systematic review. Children (Basel) 2021;8:415.
22. Lange SJ, Kompaniyets L, Freedman DS, Kraus EM, Porter R; DNP3, et al. Longitudinal trends in body mass index before and during the COVID-19 pandemic among persons aged 2-19 years - United States, 2018-2020. MMWR Morb Mortal Wkly Rep 2021;70:1278–83.
23. Bacha F, Gidding SS. Cardiac abnormalities in youth with obesity and type 2 diabetes. Curr Diab Rep 2016;16:62.
24. Kostopoulou E, Güemes M, Shah P. COVID-19 in Children and adolescents with endocrine conditions. Horm Metab Res 2020;52:769–74.
25. Lin X, Xu Y, Pan X, Xu J, Ding Y, Sun X, et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep 2020;10:14790.
26. Umpierrez G, Korytkowski M. Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol 2016;12:222–32.
27. Wolfsdorf JI, Glaser N, Agus M, Fritsch M, Hanas R, Rewers A, et al. ISPAD clinical practice consensus guidelines 2018: diabetic ketoacidosis and the hyperglycemic hyperosmolar state. Pediatr Diabetes 2018;19 Suppl 27:155–77.
28. Bonora BM, Boscari F, Avogaro A, Bruttomesso D, Fadini GP. Glycaemic control among people with type 1 diabetes during lockdown for the SARS-CoV-2 outbreak in Italy. Diabetes Ther 2020;11:1369–79.
29. Tornese G, Ceconi V, Monasta L, Carletti C, Faleschini E, Barbi E. Glycemic control in type 1 diabetes mellitus during COVID-19 quarantine and the role of in-home physical activity. Diabetes Technol Ther 2020;22:462–7.
30. Pelletier JH, Rakkar J, Au AK, Fuhrman D, Clark RSB, Horvat CM. Trends in US pediatric hospital admissions in 2020 compared with the decade before the COVID-19 pandemic. JAMA Netw Open 2021;4e2037227.
31. Scaramuzza A, Tagliaferri F, Bonetti L, Soliani M, Morotti F, Bellone S, et al. Changing admission patterns in paediatric emergency departments during the COVID-19 pandemic. Arch Dis Child 2020;105:704–6.
32. Ng SM, Woodger K, Regan F, Soni A, Wright N, Agwu JC, et al. Presentation of newly diagnosed type 1 diabetes in children and young people during COVID-19: a national UK survey. BMJ Paediatr Open 2020;4e000884.
33. Mameli C, Scaramuzza A, Macedoni M, Marano G, Frontino G, Luconi E, et al. Type 1 diabetes onset in Lombardy region, Italy, during the COVID-19 pandemic: the doublewave occurrence. EClinicalMedicine 2021;39:101067.
34. Kamrath C, Mönkemöller K, Biester T, Rohrer TR, Warncke K, Hammersen J, et al. Ketoacidosis in children and adolescents with newly diagnosed type 1 diabetes during the COVID-19 pandemic in Germany. JAMA 2020;324:801–4.
35. Dżygało K, Nowaczyk J, Szwilling A, Kowalska A. Increased frequency of severe diabetic ketoacidosis at type 1 diabetes onset among children during COVID-19 pandemic lockdown: an observational cohort study. Pediatr Endocrinol Diabetes Metab 2020;26:167–75.
36. Alaqeel A, Aljuraibah F, Alsuhaibani M, Huneif M, Alsaheel A, Dubayee MA, et al. The impact of COVID-19 pandemic lockdown on the incidence of new-onset type 1 diabetes and ketoacidosis among saudi children. Front Endocrinol (Lausanne) 2021;12:669302.
37. Lavik AR, Ebekozien O, Noor N, Alonso GT, Polsky S, Blackman SM, et al. Trends in Type 1 diabetic ketoacidosis during COVID-19 surges at 7 US centers: highest burden on non-Hispanic Black patients. J Clin Endocrinol Metab 2022;107:1948–55.
38. Chambers MA, Mecham C, Arreola EV, Sinha M. Increase in the number of pediatric new-onset diabetes and diabetic ketoacidosis cases during the COVID-19 pandemic. Endocr Pract 2022;28:479–85.
39. Modarelli R, Sarah S, Ramaker ME, Bolobiongo M, Benjamin R, Gumus Balikcioglu P. Pediatric diabetes on the rise: trends in incident diabetes during the COVID-19 pandemic. J Endocr Soc 2022;6:bvac024.
40. Chiesa V, Antony G, Wismar M, Rechel B. COVID-19 pandemic: health impact of staying at home, social distancing and 'lockdown' measures-a systematic review of systematic reviews. J Public Health (Oxf) 2021;43:e462–81.
41. Fadini GP, Morieri ML, Longato E, Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest 2020;43:867–9.
42. Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab 2020;31:1068–77.e3.
43. Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol 2022;10:311–21.
44. Müller JA, Groß R, Conzelmann C, Krüger J, Merle U, Steinhart J, et al. SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat Metab 2021;3:149–65.
45. Li J, Wang X, Chen J, Zuo X, Zhang H, Deng A. COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes Metab 2020;22:1935–41.
46. Vlad A, Serban V, Timar R, Sima A, Botea V, Albai O, et al. Increased incidence of type 1 diabetes during the COVID-19 pandemic in Romanian children. Medicina (Kaunas) 2021;57:973.
47. Oshima M, Knoch KP, Diedisheim M, Petzold A, Cattan P, Bugliani M, et al. Virus-like infection induces human β cell dedifferentiation. JCI Insight 2018;3e97732.
48. Jaeckel E, Manns M, Von Herrath M. Viruses and diabetes. Ann N Y Acad Sci 2002;958:7–25.
49. Op de Beeck A, Eizirik DL. Viral infections in type 1 diabetes mellitus--why the β cells? Nat Rev Endocrinol 2016;12:263–73.
50. Hyöty H, Leinikki P, Reunanen A, Ilonen J, Surcel HM, Rilva A, et al. Mumps infections in the etiology of type 1 (insulin-dependent) diabetes. Diabetes Res 1988;9:111–6.
51. Burke RM, Tate JE, Jiang B, Parashar UD. Rotavirus and type 1 diabetes-is there a connection? A synthesis of the evidence. J Infect Dis 2020;222:1076–83.
52. Hober D, Sauter P. Pathogenesis of type 1 diabetes mellitus: interplay between enterovirus and host. Nat Rev Endocrinol 2010;6:279–89.
53. Glanz JM, Clarke CL, Xu S, Daley MF, Shoup JA, Schroeder EB, et al. Association between rotavirus vaccination and type 1 diabetes in children. JAMA Pediatr 2020;174:455–62.
54. Rogers MAM, Basu T, Kim C. Lower Incidence rate of type 1 diabetes after receipt of the rotavirus vaccine in the United States, 2001-2017. Sci Rep 2019;9:7727.
55. Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. SARS-CoV-2: structure, biology, and structure-based therapeutics development. Front Cell Infect Microbiol 2020;10:587269.
56. Naqvi AAT, Fatima K, Mohammad T, Fatima U, Singh IK, Singh A, et al. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach. Biochim Biophys Acta Mol Basis Dis 2020;1866:165878.
57. Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol 2016;3:237–61.
58. Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol 2022;23:3–20.
59. Song W, Gui M, Wang X, Xiang Y. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLoS Pathog 2018;14e1007236.
60. Hoffmann M, Kleine-Weber H, Pöhlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 Is essential for infection of human lung cells. Mol Cell 2020;78:779–84. e5.
61. Bestle D, Heindl MR, Limburg H, Van Lam van T, Pilgram O, Moulton H, et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci Alliance 2020;3e202000786.
62. Blume C, Jackson CL, Spalluto CM, Legebeke J, Nazlamova L, Conforti F, et al. A novel ACE2 isoform is expressed in human respiratory epithelia and is upregulated in response to interferons and RNA respiratory virus infection. Nat Genet 2021;53:205–14.
63. Sims AC, Baric RS, Yount B, Burkett SE, Collins PL, Pickles RJ. Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. J Virol 2005;79:15511–24.
64. Hikmet F, Méar L, Edvinsson Å, Micke P, Uhlén M, Lindskog C. The protein expression profile of ACE2 in human tissues. Mol Syst Biol 2020;16e9610.
65. Fignani D, Licata G, Brusco N, Nigi L, Grieco GE, Marselli L, et al. SARS-CoV-2 receptor angiotensin i-converting enzyme type 2 (ACE2) Is expressed in human pancreatic β-cells and in the human pancreas microvasculature. Front Endocrinol (Lausanne) 2020;11:596898.
66. Kusmartseva I, Wu W, Syed F, Van Der Heide V, Jorgensen M, Joseph P, et al. Expression of SARS-CoV-2 entry factors in the pancreas of normal organ donors and individuals with COVID-19. Cell Metab 2020;32:1041–51. e6.
67. Coate KC, Cha J, Shrestha S, Wang W, Gonçalves LM, Almaça J, et al. SARS-CoV-2 cell entry factors ACE2 and TMPRSS2 are expressed in the microvasculature and ducts of human pancreas but are not enriched in β cells. Cell Metab 2020;32:1028–40.e4.
68. Steenblock C, Richter S, Berger I, Barovic M, Schmid J, Schubert U, et al. Viral infiltration of pancreatic islets in patients with COVID-19. Nat Commun 2021;12:3534.
69. Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol 2010;47:193–9.
70. Qadir MMF, Bhondeley M, Beatty W, Gaupp DD, Doyle-Meyers LA, Fischer T, et al. SARS-CoV-2 infection of the pancreas promotes thrombofibrosis and is associated with new-onset diabetes. JCI Insight 2021;6e151551.
71. Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol 2009;5:219–26.
72. Huo C, Xiao K, Zhang S, Tang Y, Wang M, Qi P, et al. H5N1 influenza a virus replicates productively in pancreatic cells and induces apoptosis and pro-inflammatory cytokine response. Front Cell Infect Microbiol 2018;8:386.
73. Wu CT, Lidsky PV, Xiao Y, Lee IT, Cheng R, Nakayama T, et al. SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment. Cell Metab 2021;33:1565–76.e5.
74. Tang X, Uhl S, Zhang T, Xue D, Li B, Vandana JJ, et al. SARS-CoV-2 infection induces beta cell transdifferentiation. Cell Metab 2021;33:1577–91.e7.
75. Modarelli R, Balikcioglu PG, Hendrix G, DeRusso M, Ozment C. The perfect storm: rapid progression of diabetic ketoacidosis in pediatric diabetes in the setting of COVID-19. AACE Clin Case Rep 2021;7:357–9.
76. Hadi A, Werge M, Kristiansen KT, Pedersen UG, Karstensen JG, Novovic S, et al. Coronavirus Disease-19 (COVID-19) associated with severe acute pancreatitis: case report on three family members. Pancreatology 2020;20:665–7.
77. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet 2017;390:2627–42.
78. Yatsuya H, Li Y, Hilawe EH, Ota A, Wang C, Chiang C, et al. Global trend in overweight and obesity and its association with cardiovascular disease incidence. Circ J 2014;78:2807–18.
79. Song K, Park G, Lee HS, Lee M, Lee HI, Ahn J, et al. Trends in prediabetes and non-alcoholic fatty liver disease associated with abdominal obesity among Korean children and adolescents: based on the Korea National Health and Nutrition Examination Survey between 2009 and 2018. Biomedicines 2022;10:584.
80. Suliga E. Visceral adipose tissue in children and adolescents: a review. Nutr Res Rev 2009;22:137–47.
81. Xu W, Wu J, Cao L. COVID-19 pandemic in China: context, experience and lessons. Health Policy Technol 2020;9:639–48.
82. Ahmed MZ, Ahmed O, Aibao Z, Hanbin S, Siyu L, Ahmad A. Epidemic of COVID-19 in China and associated Psychological Problems. Asian J Psychiatr 2020;51:102092.
83. Fasano MV, Padula M, Azrak MÁ, Avico AJ, Sala M, Andreoli MF. Consequences of lockdown during COVID-19 pandemic in lifestyle and emotional state of children in argentina. Front Pediatr 2021;9:660033.
84. Benmerzoug M, Djoudi B, Debbache A, Harbouche A, Dehmani ID, Djekkoun N, et al. Impact of COVID-19 lockdown on children's health in North Africa. Matern Child Health J 2022;26:1701–8.
85. Pietrobelli A, Pecoraro L, Ferruzzi A, Heo M, Faith M, Zoller T, et al. Effects of COVID-19 lockdown on lifestyle behaviors in children with obesity living in Verona, Italy: a longitudinal study. Obesity (Silver Spring) 2020;28:1382–5.
86. Valenzise M, D'Amico F, Cucinotta U, Lugarà C, Zirilli G, Zema A, et al. The lockdown effects on a pediatric obese population in the COVID-19 era. Ital J Pediatr 2021;47:209.
87. Chang TH, Chen YC, Chen WY, Chen CY, Hsu WY, Chou Y, et al. Weight gain associated with COVID-19 lockdown in children and adolescents: a systematic review and metaanalysis. Nutrients 2021;13:3668.
88. Cipolla C, Curatola A, Ferretti S, Giugno G, Condemi C, Delogu AB, et al. Eating habits and lifestyle in children with obesity during the COVID19 lockdown: a survey in an Italian center. Acta Biomed 2021;92e2021196.
89. Chao LC, Vidmar AP, Georgia S. Spike in diabetic ketoacidosis rates in pediatric type 2 diabetes during the COVID-19 Pandemic. Diabetes Care 2021;44:1451–3.
90. Minhas D, Subbarayan A, Sundaram P. 627. Are greater numbers of children with newly diagnosed type 2 diabetes mellitus a further example of collateral damage from the COVID-19 pandemic? ArcDis Child 2021;106:A64.
91. Marks BE, Khilnani A, Meyers A, Flokas ME, Gai J, Monaghan M, et al. Increase in the diagnosis and severity of presentation of pediatric type 1 and type 2 diabetes during the COVID-19 pandemic. Horm Res Paediatr 2021;94:275–84.
92. Chowdhury TA. Diabetes and COVID-19: diseases of racial, social and glucose intolerance. World J Diabetes 2021;12:198–205.
93. Eberle C, Stichling S. Impact of COVID-19 lockdown on glycemic control in patients with type 1 and type 2 diabetes mellitus: a systematic review. Diabetol Metab Syndr 2021;13:95.
94. Brambilla I, Delle Cave F, Guarracino C, De Filippo M, Votto M, Licari A, et al. Obesity and COVID-19 in children and adolescents: a double pandemic. Acta Biomed 2022;93(S3):e2022195.
95. Stavridou A, Kapsali E, Panagouli E, Thirios A, Polychronis K, Bacopoulou F, et al. Obesity in children and adolescents during COVID-19 pandemic. Children (Basel) 2021;8:135.
96. Bhattacharya S, Aggarwal P, Bera OP, Saleem SM, Shikha D, Vallabh V, et al. COVID-19 and childhood obesity (COBESITY) in the era of new normal life: a need for a policy research. J Public Health Res 2021;10(s2):jphr.2021.2673.
97. Peric S, Stulnig TM. Diabetes and COVID-19: diseasemanagement-people. Wien Klin Wochenschr 2020;132:356–61.
98. Kazakou P, Lambadiari V, Ikonomidis I, Kountouri A, Panagopoulos G, Athanasopoulos S, et al. Diabetes and COVID-19; a bidirectional interplay. Front Endocrinol (Lausanne) 2022;13:780663.
99. Salmi H, Heinonen S, Hästbacka J, Lääperi M, Rautiainen P, Miettinen PJ, et al. New-onset type 1 diabetes in Finnish children during the COVID-19 pandemic. Arch Dis Child 2022;107:180–5.
100. Raffaldi I, Castagno E, Fumi I, Bondone C, Ricceri F, Besenzon L, et al. Pediatric admissions to emergency departments of North-Western Italy during COVID-19 pandemic: a retrospective observational study. Lancet Reg Health Eur 2021;5:100081.
101. Bronson SC. Practical scenarios and day-to-day challenges in the management of diabetes in COVID-19 - Dealing with the 'double trouble'. Prim Care Diabetes 2021;15:737–9.
102. Vanelli M, Chiari G, Lacava S, Iovane B. Campaign for diabetic ketoacidosis prevention still effective 8 years later. Diabetes Care 2007;30e12.
103. d'Annunzio G, Maffeis C, Cherubini V, Rabbone I, Scaramuzza A, Schiaffini R, et al. Caring for children and adolescents with type 1 diabetes mellitus: Italian Society for Pediatric Endocrinology and Diabetology (ISPED) statements during COVID-19 pandemia. Diabetes Res Clin Pract 2020;168:108372.

Article information Continued

Fig. 1.

RS-CoV-2 enters the pancreatic β cell and activates β-cell intracellular signaling, inducing processes that end in apoptosis, insulitis, and transdifferentiation into α cells and acinar cells. SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2; ACE2, angiotensin converting enzyme 2; NRP-1, neuropilin-1; PAK, p21-activated kinase; JNK, c-Jun N-terminal kinases; PKR, protein kinase R; ELF2α, eukaryotic translation initiation factor 2 subunit 1; ISR, integrated stress response.

Table 1.

Summary of reviewed studies about the impact of COVID-19 pandemic on diabetes presentation at diagnosis

Reference Type of study % of DKA and severe DKA at diabetes diagnosis in 2019 % of DKA and severe DKA at diabetes diagnosis in 2020 Documented SARS-CoV-2 infection in 2020 Outcomes
Rabbone et al. [10] Cross-sectional 41% (36%: severe DKA) 38% (44.3%: severe DKA) 5% of patients had laboratory confirmation of SARS- CoV-2 infection (RT-PCR or antibodies). A higher proportion of severe DKA was observed during COVID-19 pandemic.
Mameli et al. [33] Prospective multicenter study 34.4% (36.9%: severe DKA) 45.3% (42.9%: severe DKA) Not all patients performed nasopharyngeal swab for SARS-CoV-2. The proportion of both DKA and severe DKA augmented during the pandemic.
Dżygało et al. [35] Cohort study 40.3% (28.6%: severe DKA) 52.9% (61.1%: severe DKA) None of the patients tested positive. The proportion of both DKA and severe DKA augmented during the pandemic.
Ng et al. [32] Retrospective study 38% 51% (28%: severe DKA) Not known A higher proportion of DKA w as obser v ed dur ing COVID-19 pandemic.
Alaqeel et al. [36] Retrospective multi-center cohort study 13.4% (16.6%: severe DKA) 26% (30.4%: severe DKA) Not known An increased DKA frequency was observed during the pandemic.
Chambers et al. [38] Single -center retrospective observational study 48% (30%: severe DKA) 60% (46%: severe DKA) RT-PCR tests were performed in 72% of patients. 12% of them tested positive during hospitalization. An increase in DKA and severe DKA cases was observed. COVID -19 might have a diabetogenic effect.

COVID-19, coronavirus disease 2019; DKA, diabetic ketoacidosis: SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2; RT-PCR, reverse transcription-polymerase chain reaction.